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ABSTRACT
Whole-genome resequencing is still a costly
method to detect genetic mutations that lead to
altered forms of proteins and may be associated
with disease development. Since the majority of
disease-related single nucleotide variations (SNVs)
are found in protein-coding regions, we propose to
identify SNVs in expressed exons of the human
genome using the recently developed RNA-Seq
technique. We identify 12176 and 10621 SNVs,
respectively, in Jurkat T cells and CD4
+ T cells
from a healthy donor. Interestingly, our data show
that one copy of the TAL-1 proto-oncogene has a
point mutation in 3’ UTR and only the mutant allele
is expressed in Jurkat cells. We provide a compre-
hensive dataset for further understanding the
cancer biology of Jurkat cells. Our results indicate
that this is a cost-effective and efficient strategy to
systematically identify SNVs in the expressed
regions of the human genome.
INTRODUCTION
Mutations in DNA sequence can alter or disrupt cellular
function and lead to disease development through various
pathways depending on their genomic location. Although
mutations in noncoding regions may disrupt functional
cis-regulatory elements that control transcription and
lead to altered transcript levels, the majority of genetic
diseases identiﬁed so far are linked to mutations in protein
coding regions of the genome that lead to altered forms
of proteins. Whole-genome resequencing of individual
human genome at a high-enough coverage should be
able to determine most of single nucleotide polymor-
phisms (SNPs) as well as somatic point mutations in
coding and noncoding regions (1). However, it is very
costly to do so at present. Since the majority of human
genome mutations associated with diseases are either
missense/nonsense or aﬀecting splicing in only about 2%
of the human genome (2), it would signiﬁcantly reduce
cost and increase eﬃciency by resequencing the exonic
regions. We propose to identify point mutations in the
expressed coding regions of the human genome by
sequencing cDNAs using RNA-seq. This strategy can
provide both the gene expression and single nucleotide
variation (SNV) information at the same time. Since
expressed regions constitute only a minor fraction of the
human genome, suﬃcient coverage of these regions can be
achieved at low sequencing cost using the next-generation
sequencing technologies. Our data demonstrate that this
approach eﬃciently identiﬁes SNVs that alter protein
sequence.
MATERIALS AND METHODS
Sample preparation and RNA sequencing
mRNAs isolated from Jurkat T cells, derived from acute
lymphoblastic leukemia (ALL), and CD4
+ T cells from a
healthy donor, were converted to cDNA using standard
protocols. The cDNAs were fragmented to 100–200bp
using sonication, followed by end repair and Solexa adap-
tor ligation. The products were sequenced on an Illumina
GAII system according to established procedures (3–6).
Short reads alignment
The short reads were analyzed as outlined in Figure 1. The
quality-ﬁltered 30-bp short sequence reads were aligned to
the reference sequence consisting of hg18 (NCBI Build 36)
human genome plus a library of synthetic exon junction
sequences using ELAND (Eﬃcient Local Alignment
of Nucleotide Data) software, allowing up to two mis-
matches with the reference sequence. There are three
types of uniquely aligned reads: U0 reads that align per-
fectly to the reference sequence, U1 reads that have one
mismatch with the reference sequence and U2 reads
that have two mismatches with the reference sequence.
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are U2 reads. The library of exon junction sequences was
created as follows. Human exon sequences were retrieved
from Ensembl database (release 50). We joined all possible
pairs of exons that belong to the same transcript such that
the genomic order of exons is respected. A junction
sequence consists of last 26bp of 50 exon and ﬁrst 26bp
of 30 exon. Redundant sequences were removed from the
resulting set of 52-bp exon junction sequences.
Redundant reads filtering
In order to remove possible PCR ampliﬁcation artifacts
and to reduce confounding eﬀects of systematically bad
sequencing cycles in short sequence reads, the following
two consecutive ﬁlters were applied to the set of uniquely
aligned reads (Figure 2A).
(i) Retain only a single copy of each read. (A read is
deﬁned as a string of letters A, C, G, T and N.)
(ii) There can still be multiple U1 and U2 reads that
passed Filter 1 at the same genomic location. (Note
that there can be at most one single U0 read
that passed Filter 1 at each genomic location).
Randomly select only one read each from U1 and
U2 reads that map to the same location.
As a result of application of ﬁlters 1 and 2, at most
three reads are retained at any given genomic location
(Figure 3A). However, the stringent procedure of ran-
domly selecting at most one read from U1 and U2 reads
that map to the same location should not signiﬁcantly
reduce the statistical power to detect SNVs. As can be
seen from the example in Figure 3A, there can be plenty
of overlapping but noncoincident reads that cover an
SNV. In fact, for reads of length 30bp there can be as
many as 3 30=90 reads that cover an SNV. Since
90-fold coverage is the upper-bound for coverage possible
by ﬁltered reads, the number of reads in very highly
expressed exons will not correspond to actual expression
levels. However, it should not be a concern because the
Figure 2. Redundant Reads Filter and SNV probability calculation
examples. (A) There are nine reads that map uniquely to the same
genomic location (top box). Nucleotide mismatches with reference
sequence are highlighted in red. Filter 1 retains a single copy of each
read. Thus, only ﬁve reads remain after Filter 1 is applied (middle box).
There are two U1 reads, two U2 reads and one U0 read in the middle
box. Filter 2 randomly selects one U1, one U2 and one U0 read.
This leaves three reads at the same genomic location (bottom box).
(B) Example of SNV probability calculation. Colored in red is a can-
didate SNV site. Seven short reads map uniquely to that site. The
reference nucleotide is T. Five reads have nucleotides that diﬀer from
the reference nucleotide and two reads have nucleotide T at the candi-
date SNV site. Let the error rate estimated from the total number of
U0, U1 and U2 nonredundant reads be q=0.02. The binomial
(random chance) probability to observe two matches and ﬁve mis-
matches at the same location is proportional to q
5 (1 q)
2. The
P-value is given by the binomial probability of observing ﬁve or
more mismatches in a seven-read alignment and it is equal to
6.5 10
–8.
Figure 1. The ﬂow chart of single nucleotide variations identiﬁcation in
expressed exons using RNA-Seq.
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tive rate of SNV detection and 90-fold coverage is a very
signiﬁcant coverage. By restricting the number of reads
that can map to the same genomic location, we allow
the evidence for presence of SNV come mainly from over-
lapping but noncoincident reads.
In order to further justify our use of Filter 1+Filter2,
we compared the numbers of known and unknown SNVs
detected using the following four diﬀerent ﬁltering
procedures:
(a) Apply Filter 1 and then randomly select one read
each from U1 and U2 categories. This is our
Filter 1+Filter 2.
(b) Apply Filter 1 and then randomly select two reads
each from U1 and U2 categories.
(c) Apply Filter 1 and then randomly select three reads
each from U1 and U2 categories.
(d) No ﬁlter is applied.
We applied these four ﬁlters to unique reads from
CD4
+ sample. The results shown in Figure 3B suggest
that Filters B–D lead to signiﬁcant increase in the
number of false positives while only marginally increasing
number of true positives. Let us argue that the last state-
ment is indeed true. Exons expressed in CD4
+ cells con-
tain SNVs. Some of these SNVs are known SNVs, i.e.
previously annotated in dbSNP database, while some
SNVs are novel, i.e. previously unknown SNVs. Let the
ratio of number of unknown to known SNVs in expressed
exons be U:K. An SNV-detection algorithm blind to the
distinction between known and unknown SNVs will detect
a certain number of SNVs. Let Kd and Ud be numbers
of detected known and unknown SNVs, respectively.
We expect that the ratio Ud:Kd is comparable to U:K.
The fact that Ud:Kd ratio for SNVs detected following
the ﬁlters B, C or D is signiﬁcantly higher than the corre-
sponding ratio for ﬁlter A implies that a large fraction of
novel SNVs detected following the ﬁlters B–D are actually
false positives. Note that false-positive rate among
detected known SNVs is low since the probability of
sequencing errors occurring at precisely dbSNP SNP loca-
tions with the right alternative allele is small. This is sup-
ported by the fact that the number of detected known
SNVs is not very sensitive to the ﬁltering procedure used
(see Figure 3B).
Assigning statistical significance to candidate SNV sites
The overall error rate of sequencing for each sample
is estimated as the frequency of nucleotide mismatches.
Using numbers of matches and mismatches from
Table 1, the sequencing error rates for Jurkat and
CD4
+ samples are estimated to be 0.017 and 0.019,
respectively. We use a simple binomial distribution
to model null distribution of number of mismatches at a
genomic locus with N uniquely aligned reads (Figure 2B).
This model assumes that error rate is independent of the
position in the read. It should be straightforward to
extend our model to a model with position-dependent
error rate.
Since there are a large number of candidate variant
sites, nominal P-values calculated using the binomial
null distribution need to be adjusted for multiple statisti-
cal testing. We used a very conservative multiple-
testing procedure—Bonferroni method–to adjust nominal
P-values. With around 6 million candidate variant
sites, Bonferroni-adjusted P-value 0.01 corresponds to
the nominal P-value 0.01/6000000=1.7 10
–9. In this
paper, we called a variant site signiﬁcant if the nominal
Figure 3. Demonstration that Redundant Reads Filter is necessary.
(A) As described in ‘Material and methods’ section, application of
redundant reads ﬁlter (Filter 1 + Filter 2) to uniquely mapped reads
leaves at most three reads at a given genomic location: one U0, one U1
and one U2 read. By restricting the number of reads that can map to
the same genomic location, we reduce false-positive rate of SNV detec-
tion. The evidence for presence of SNV comes mainly from overlapping
but noncoincident reads. There are many overlapping but noncoinci-
dent reads that can cover a single SNV. In fact, there can still be as
many as 90 reads of length 30bp that cover a single SNV after the
ﬁltering step. Thus, the statistical power to detect the SNV is not
reduced by the ﬁltering procedure. (B) The number of detected
(P-value=10
–9) known, i.e. SNPs from dbSNP database, and
unknown (novel) SNVs using reads ﬁltered using four diﬀerent ﬁlters:
Filter A is the Redundant Reads Filter; Filter B is Filter 1 followed by
randomly selecting two reads each from U1 and U2 categories; Filter C
is Filter 1 followed by randomly selecting three reads each from U1
and U2 categories; the last ﬁlter is an empty ﬁlter, i.e. no ﬁltering of
unique reads is done. The number of detected known SNVs is not
sensitive to the ﬁltering method used, conﬁrming very low false-positive
rate among detected known SNVs. However, the number of detected
unknown SNVs is much higher for the cases of Filters B, C and No
ﬁlter than for Filter A, demonstrating high false-positive rates resulting
from the use of these alternative ﬁlters. Thus, Filter A is the best of
four ﬁlters.
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–9. There are less conservative
multiple-testing procedures available such as Benjamini–
Hochberg method. These less conservative methods
should be used to test statistical signiﬁcance of candidate
SNV sites with low reads coverage. In addition, the posi-
tion dependence of error rates in short reads cannot be
ignored for SNV sites with low reads coverage.
Cost analysis for SNV detection
The theoretical upper bound for the number of SNVs
detectable using cDNA of expressed exons in a tissue is
given by the number M of all SNVs contained in the
expressed exons of the tissue. At a given sequencing
depth D, a fraction F of these M SNVs will be detected.
We estimate the curve F(D) as follows. Let N be the total
number of nonredundant unique 30-bp sequenced reads.
In order to avoid the problem of double counting
in regions where exons overlap, we merge all Ensembl
exons and consider merged exonic regions. For each
merged exonic region Ek, we compute reads per kilobase
of exon model per million mapped reads (3) RPKM value
Rk of its expression as Rk=(10
9 Nk)/(N Lk), where Nk
is the number of nonredundant unique reads in Ek and Lk
is the length of Ek. At the sequencing depth we achieved
(400Mbp  13 million nonredundant unique 30-bp
genomic reads in CD4
+ sample), we compute Rk for all
merged exonic regions. We then assume that Rk value is
independent of sequencing depth. We validated the latter
assumption by comparison of Rk values computed using
full CD4
+ data set and 50% of the dataset (= four lanes
of Solexa data). The Pearson correlation coeﬃcient for
this comparison is found to be >0.99.
Given the sequencing depth D, exon expression level Rk
can be used to estimate coverage Ck of the exon by
sequence reads. At the sequencing depth D, the expected
number of 30-bp nonredundant unique reads in the exon
is Nk=(Rk D Lk)/(30 10
9). Thus, the expected cov-
erage at sequencing depth D is given by Ck=(30 Nk)/
Lk=(Rk D)/10
9.
The stringent P-value cutoﬀ 10
–9 used in this paper is
related to fold coverage C as follows. The P-value for a
heterozygous SNV with wt to mutant reads ratio 7:7 is
 10
–9 when sequencing error rate is q=0.019 (see exam-
ple in Figure 2B). Thus, our P-value cutoﬀ 10
–9 corre-
sponds to the fold coverage threshold C=14. For
sequencing depth that we achieved, D=400Mbp, cover-
age fold C=14 corresponds to RPKM value  35. Thus,
heterozygous SNVs in exonic regions with RPKM <35 are
undetectable at the sequencing depth D=400Mbp and
P-value cutoﬀ 10
–9. It is easier to detect homozygous
SNVs. At the sequencing error rate q=0.019, homozy-
gous SNV with wt to mutant reads ratio 0:5 has P-value
 10
–9. The coverage C=5 corresponds to RPKM
value  13.
With a large enough sequencing depth, most SNVs in
expressed exons will eventually be detected. It has been
shown in (3) that RPKM value 1 corresponds approxi-
mately to one transcript per cell. We thus assume that
an exonic region Ek is expressed if its RPKM value Rk
  1. The total size of merged exonic regions with RPKM
  1i s 35Mbp which is about 50% of all merged exonic
regions ( 69Mbp) in the human genome. Since SNVs
should be more or less uniformly distributed in exonic
regions, we introduce the density   of SNVs per base
pair of exonic region. The expected number of SNVs in
the exonic region Rk is thus equal to   Lk. Given a SNV
detection fold coverage threshold C, we assume that all
SNVs in an exonic region Rk are detected once the fold
coverage Ck of the region exceeds the threshold C. As the
sequencing depth increases, more and more exonic regions
pass coverage threshold. The expected fraction F(D)o f
expressed SNVs detected at the sequencing depth D is
given by the equation:
FðDÞ¼ð 1=ZÞkðCk > CÞ Lk   ðRk   1Þ,
where Ck=(Rk D)/10
9, Z=kLk (Rk 1) is the
total size (in bp) of expressed merged exonic regions and
the function  of the Boolean variable is given by
(true)=1, (false)=0. In this manner, we derived the
SNV detection cost curve 100 F(D) shown in Figure 4B.
Exon sequencing coverage analysis
The coverage analysis results shown in Figure 4A were
obtained as follows. In order to avoid double-counting
sequencing tags in the regions where exons overlap, we
merged all exons and considered merged exonic regions.
For each contiguous exonic region Ek we compute
Table 1. Miscellaneous information about short sequence reads and
single nucleotide variant sites detected in Jurkat and CD4
+ T cell
samples using RNA-seq data
Jurkat CD4
Number of unique genomic reads 26275213 27253288
Number of unique exon-junction reads 2451140 2267059
Number of unique and nonredundant
genomic reads
13166074 13325274
Number of unique and nonredundant
junction reads
1166914 924220
Number of matched bases 422487847 419253929
Number of mismatched bases 7501793 8230891
Number of variant sites 5477131 6030145
Number of signiﬁcant variant sites 12176 10621
Number of novel signiﬁcant variant sites 4703 2952
Number of nonsynonymous mutations 3206 1977
Number of novel nonsynonymous mutations 1770 747
Number of nonsense mutations 47 17
Number of novel nonsense mutations 41 9
Number of splice-site mutations 66 31
Number of novel splice-site mutations 60 23
Miscellaneous information about short sequence reads and single
nucleotide variant sites detected in Jurkat and CD4
+ T cell samples
using RNA-seq data.
The number of unique and nonredundant reads refers to the number of
uniquely mapped reads that pass Redundant Reads Filter.
The number of mismatched bases refers to the total number of bases in
unique nonredundant reads that mismatch with the reference sequence;
it is given by the formula: number of U1 reads+twice the number of
U2 reads.
The number of variant sites refers to the total number of genomic
locations where mismatches with short sequence reads were observed.
‘Signiﬁcant’ means signiﬁcant at P-value<1.0 10
–9.
‘Novel’ means not present in dbSNP build 126 database.
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the number of unique and non-redundant 30-bp sequenc-
ing reads detected in the region and Lk is the length of
the region. The fraction P of exonic regions passing
sequencing coverage threshold C is deﬁned as the ratio
of the total size of exonic regions covered at least C-fold
to the total size of all exonic regions: P(C)=(1/L)k
(Ck C) Lk, where L= kLk.
Annotation of significant SNV sites
Genome sequence ﬁles, and Ensembl and RefSeq gene
annotations tables for hg18 human genome were
downloaded from UCSC Genome Bioinformatics website:
http://genome.ucsc.edu. We determined synonymous/
nonsynonymous status of SNVs based on the codon
changes resulting from nucleotide substitutions. An SNV
was annotated to be a splice-site SNV if it lies in the ﬁrst
or last 2bp of an intron.
Software and data set
We implemented Redundant Reads Filter and Point
Mutation Analyzer in UNIX shell, Perl and C++. The
entire suite of software is available at: http://dir.nhlbi.nih.
gov/papers/lmi/epigenomes/pma. On the Dell Precision
T7400 Linux workstation, the analysis of 27 million
unique reads from CD4
+ sample took only 12min:
8min at ﬁltering step using Redundant Reads Filter and
4min for assembly of reads, SNV detection and assigning
signiﬁcance P-values to SNVs using Point Mutation
Analyzer. As an input, the algorithm uses ELAND results
ﬁles from Illumina Genome Analyzer. We deposited raw
and processed data set for Jurkat and CD4
+ T cells to
Gene Expression Omnibus (GEO) database under acces-
sion number GSE16190.
RESULTS AND DISCUSSIONS
Reads mapping, redundancy filtering and SNV detection
In order to detect SNVs in the protein-coding and
untranslated regions of the human genome using the
next generation sequencing techniques, we designed a
strategy as outlined in Figure 1. cDNAs synthesized
from mRNAs were fragmented to 100–200bp by sonica-
tion and sequenced using Illumina Genome Analyzer II.
The short reads of 30bp were mapped to the reference
consisting of hg18 human genome plus a collection of
synthetic exon junctions using ELAND software, allowing
up to two mismatches with the reference (see ‘Materials
and methods’ section).
The mismatches with the reference sequence can occur
due to sequencing errors or point mutations present in the
sample. In order to distinguish between these two possibi-
lities and hence ﬁlter noise from signal, we applied the
following two-step procedure to the set of uniquely
mapped reads (see ‘Materials and methods’ section).
Multiple identical copies of a read can be present as an
artifact of PCR ampliﬁcation procedure and this can pro-
vide false evidence for variant site discovery. Therefore, in
the ﬁrst step, we retained only a single copy of each read
(Figure 2A). This ﬁlter can also reduce confounding eﬀects
of systematically bad sequencing cycles within a read. In
the second step, if multiple reads map to the same genomic
position, we randomly selected only one read from each of
the categories U0, U1 and U2 (Figure 2A). Thus, there
can be at most three reads that map to the same genomic
position (Figure 3A). The application of the above two
ﬁlters (named together as ‘Redundant Reads Filter’ in
Figure 1) should reduce false-positive rate of SNV discov-
ery. Since there can be only a small number of unique and
nonredundant genomic reads at the exon edges, we gener-
ated a library containing exon junctions to detect potential
SNVs in these genomic regions, which increased the power
Figure 4. Reads coverage analysis and cost analysis of SNV detection.
(A) Percentage of exonic sequences passing coverage threshold. Three
curves correspond to diﬀerent numbers of uniquely mapped nonredun-
dant reads: 13 million (Jurkat), 7 million (random subsample of 50%
Jurkat reads) and 26 million (Jurkat + CD4). For example, about 30%
of exonic regions are covered at least 5-fold by nonredundant uniquely
mapped reads in Jurkat sample. In the combined Jurkat and CD4
sample, about 40% of exonic regions are covered at least 5-fold.
(B) Two curves correspond to estimates of sequencing costs for homo-
zygous (red curve) and heterozygous (blue dotted curve) SNV detection
in CD4
+ sample. About 80% of all homozygous SNVs in expressed
(RPKM   1) exons can be detected using 67 million 30-bp nonredun-
dant unique reads ( 2000Mbp). At this sequencing depth, about
55% of all heterozygous SNVs in expressed exons can be detected.
(See ‘Materials and methods’ section for details on derivation of cost
curves).
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6% of all signiﬁcant SNVs are detected due to exon-
junction reads. The nonredundant reads were analyzed
by our point mutation analyzer. A very small probability
of observing multiple overlapping but noncoincident short
sequence reads agreeing at a given mismatched genomic
location by random chance is taken as the evidence in
favor of the presence of a genuine SNV at that location
(Figure 2B and ‘Materials and methods’section).
The number of reads that align uniquely to the genome
and exon junctions is shown in Table 1. We obtained
about 27 million uniquely mapped 30-bp sequence reads
for each sample. The resulting mean coverage of exonic
regions is  11 . Since gene expression varies dramati-
cally, we examined the distribution of coverage for all
exonic sequences (Figure 4A). Our data indicate that
with 26 million uniquely mapped non-redundant short
sequence reads, about 40% of exonic regions were covered
 5 times.
We performed sequencing cost analysis for SNV detec-
tion (see ‘Materials and methods’ section). We show that
at the stringency we use to call SNV (P-value=10
–9),
fold coverage of C=5 and C=14 are needed to detect
homozygous and heterozygous SNVs, respectively. At the
sequencing depth we achieved (around 13 million 30-bp
unique nonredundant reads), these fold coverages corre-
spond to RPKM values 13 and 35, respectively. Thus,
we estimate that about 40% of homozygous and 14% of
heterozygous expressed SNVs were detected in this work.
Our analysis demonstrates that about 80% of homozy-
gous and 55% of heterozygous SNVs in expressed exons
can be detected using 67 million 30-bp nonredundant
unique reads (Figure 4B). However, our hypothesis is
that mutation of a highly expressed gene may have more
functional consequence than a gene expressed at low level
or not expressed; therefore, it may not be necessary to do
much deeper sequencing than what we have achieved in
this study.
SNV validation and annotation
At a very stringent signiﬁcance threshold (P-value<
1.0 10
–9), we detected 12176 and 10621 SNV in Jurkat
and CD4
+ T cells, respectively. Many of detected sites
overlap with known single nucleotide polymorphism
sites (dbSNP build 126): 7473 for Jurkat and 7669 for
CD4
+ T cells (Figure 5A). Interestingly, more nonsynon-
ymous SNVs in Jurkat cells as compared to CD4
+ T cells
(Figure 5B and Tables 1, S1 and S2 for further details),
which could be related with the disease or generated
during in vitro culture.
To validate the genetic mutations detected using RNA-
Seq, we randomly selected ﬁve nonsynonymous SNVs that
are also present in dbSNP and four SNVs that are novel in
Jurkat cells (Table 2). The genomic regions containing
these SNVs were ampliﬁed using PCR and sequenced
using Sanger sequencing method. Our results indicate
that all the nine SNVs were conﬁrmed (Figure S1).
Interestingly, the SNV identiﬁcation indicated existence
of only the mutated allele in the TAL1 gene that is impli-
cated in T-cell acute leukaemia (7). However, the Sanger
sequencing revealed that both the wild-type and mutated
alleles were present, suggesting that only one parental
copy is mutated and it is the mutated allele but not the
wild-type allele that is expressed in Jurkat cells.
Among all the 12176 SNVs identiﬁed in Jurkat
cells, 4703 are novel and 7473 are known (Figure 5B).
Among these, we detected 3206 nonsynonymous and
47 nonsense mutations. Further analysis of the 47 non-
sense SNVs indicates that 41 are novel. Interestingly, all
the 20 Jurkat-speciﬁc nonsense SNVs are single-allele
changes (Table 3). We were able to PCR amplify genomic
regions containing 18 of these 20 SNVs and obtained their
sequences using Sanger sequencing method. Our results
indicate that 16 SNVs were conﬁrmed (Figure S1).
Interestingly, we found that one of the two SNVs not
conﬁrmed by sequencing of genomic DNA was in fact
present in mRNA as revealed by Sanger sequencing of
cDNA (Figure S2). The SNV is located in the last exon
of TAF6 gene. These results suggest that the SNV may be
introduced by RNA-editing.
Mutations aﬀecting splicing events are linked to a large
number of genetic diseases (2). RNA-seq can be used to
detect SNVs overlapping with potential splicing sites if the
corresponding intron sequence is present at a suﬃciently
high level in cDNA. This can happen if (1) the gene is
highly expressed so that there is a suﬃcient amount of
pre-spliced RNA present, and/or (2) as a consequence of
the splice-site mutation itself the intron is retained due to
Figure 5. Summary of results. (A) Venn diagram of single nucleotide
variants (SNVs) detected in Jurkat and CD4 samples. (B) Summary
table of SNVs detected in Jurkat and CD4 samples. Shown in the
brackets are numbers of SNVs that are novel, i.e. not present in
dbSNP Build 126 database.
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and CD4 cells, respectively, which overlapped with splice
sites and may lead to aberrant splicing process
(Figure 5B). However, using exon body and junction
reads, we did not observe any signiﬁcant Jurkat-speciﬁc
aberrant splicing events such as exon-skipping and intron
retention at the sites of splicing variants (data not shown).
CONCLUSIONS
Even though whole-genome resequencing can provide
unbiased information on SNVs in the human genome, it
is still very expensive and time consuming. Additionally,
the vast majority of genetic mutations linked to human
diseases have been found in protein-coding regions,
which make less than 2% of the human genome.
Therefore, sequencing methods that are selective for
protein-coding regions may signiﬁcantly increase the eﬃ-
ciency and reduce the cost of identifying disease-related
mutations. Since a genetic disease may be related with
increased or decreased expression of a protein or a
change in protein structure, sequencing the mRNAs may
be a satisfying strategy because it can reveal the informa-
tion of both gene expression and DNA sequence changes
in the protein-coding regions of the human genome.
In this report, we have demonstrated that analyzing
mRNAs using the next-generation sequencing techniques
is an eﬃcient and cost-eﬀective method to identify SNVs
in the protein-coding regions of the human genome, in
addition to providing the expression information of the
genome. Hence, it can be applied to identifying DNA
changes in genetic diseases associated with expressed
Table 3. Jurkat-speciﬁc nonsense mutations
Chromosome Position Gene Mutant
allele
WT
allele
Jurkat reads
variant:WT
CD4 reads
variant:WT
Conﬁrmed
chr22 37212044 DDX17 A G 32:33 0:60 Yes
chr16 29995227 PPP4C T C 28:34 0:22 Yes
chr14 90841906 CCDC88C A G 18:17 1:37 Yes
chr4 39921882 RHOH T C 19:21 0:47 Yes
chr17 77118842 C17orf70 A G 17:19 0:19 Yes
chr19 1426114 C19orf25 A G 16:11 0:13 Yes
chr20 61840255 LIME1 T G 18:25 0:65 Yes
chr19 12647448 MORG1 T C 15:12 0:11 Yes
chr14 77004596 AHSA1 A G 14:49 0:25 Yes
chr1 151902223 ILF2 A G 17:50 0:24 Yes
chr8 144728307 NAPRT1 A G 13:14 0:11 Yes
chr20 62175757 RGS19 A G 12:15 0:46 Yes
chr9 130824412 SH3GLB2 A G 11:23 0:18 Yes
chr12 119100858 GCN1L1 A G 10:16 0:16 Yes
chr17 77642429 FASN A G 11:40 0:13 —
chr12 8126211 NECAP1 A C 8:9 0:21 Yes
chr7 99543029 TAF6 A G 9:24 0:24 Yes
a
chr17 40583130 HEXIM1 T C 9:25 0:42 Yes
chr5 79534492 SERINC5 T G 8:17 0:17 No
chr9 33437492 AQP3 A C 10:26 0:65 —
aConﬁrmed by Sanger sequencing of cDNA.
Table 2. Conﬁrmation of selected Jurkat single nucleotide variants by Sanger sequencing of genomic DNA
Gene Chromosome Position
a Predicted
allele
b
Reference
allele
c
#A #C #G #T P-value Known
SNP
Amino acid
change
Conﬁrmed
LCP1 chr13 45606292 C T 0 58 0 0 1.0e-102 Yes K!E Yes
LOC554226 chr2 132729041 C T 2 53 1 1 1.9e-97 No intronic Yes
ECH1 chr19 44013927 G T 0 0 55 1 1.1e-95 Yes E!A Yes
SEPT9 chr17 73006300 G A 0 1 50 0 2.1e-90 Yes M!V Yes
POLR3K chr16 43517 C A 0 48 2 0 1.2e-88 Yes S!A Yes
CYC1 chr8 145222820 G A 0 0 49 0 7.0e-87 Yes M!V Yes
FLNA chrX 153235779 A G 45 3 2 0 4.7e-82 No R!W Yes
MYO1G chr7 44983146 T C 0 0 3 36 2.7e-69 No V!M Yes
TAL1 chr1 47456811 T C 0 0 0 39 2.7e-69 No UTR Yes
aShows 1-based chromosomal location of SNV.
bShows the allele inferred from RNA-seq data using the Point Mutation Analyzer.
cShows the allele from hg18 (NCBI Build 36) human genome sequence; both alleles refer to the forward strand of the genome sequence.
#‘X’ denotes the number of uniquely mapped nonredundant RNA-seq reads that have nucleotide X at the location of SNV.
‘Known SNP’ status is based on dbSNP build 126 database.
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